Does Rallies show Form 4 insider transactions for OTLK?

Yes. Rallies tracks OTLK insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is OTLK research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OTLK. It does not provide personalized investment advice.

OTLK (Outlook Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Outlook Therapeutics, Inc. Common Stock (OTLK) is a publicly traded Healthcare sector company. As of May 21, 2026, OTLK trades at $0.27 with a market cap of $27.70M and a P/E ratio of -0.23. OTLK moved +18.21% today. Year to date, OTLK is -49.69%; over the trailing twelve months it is -83.94%. Its 52-week range spans $0.16 to $6.98. Analyst consensus is buy with an average price target of $3.25. Rallies surfaces OTLK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading OTLK stock inside the company?

Recent OTLK insider activity includes KENYON LAWRENCE A bought 5.00K, Haddadin Yezan Munther bought 1.88K, Evanson Jeff bought 62.48K, and Dagnon Terry sold 520.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

OTLK Key Metrics

Key financial metrics for OTLK
Metric	Value
Price	$0.27
Market Cap	$27.70M
P/E Ratio	-0.23
EPS	$-1.13
Dividend Yield	0.00%
52-Week High	$6.98
52-Week Low	$0.16
Volume	109.08K
Avg Volume	0
Revenue (TTM)	$1.41M
Net Income	$-60.96M
Gross Margin	-85.05%

Recent OTLK Insider Trades

KENYON LAWRENCE A bought 5.00K (~$28.45K) on Sep 26, 2024.
Haddadin Yezan Munther bought 1.88K (~$22.24K) on Mar 28, 2024.
Evanson Jeff bought 62.48K (~$26.24K) on Mar 7, 2024.
Dagnon Terry sold 520.00K (~$590.20K) on Apr 20, 2023.

Latest OTLK News

Outlook Therapeutics Narrows Q2 Loss to $4.5M, Swiss LYTENAVA Deal — May 15, 2026
Outlook Therapeutics Raises $5M via 16.13M Share Offering, Lowers Warrants to $0.31 — Apr 23, 2026
Outlook Therapeutics Launches Best-Efforts Offering of Stock and Warrants Via H.C. Wainwright — Mar 23, 2026
Outlook Therapeutics Raises $18.4M Note, Extends Convertible Debt to December 2026 — Mar 16, 2026
Outlook Therapeutics Q1 Net Loss Narrows to $13.5M Adjusted as LYTENAVA Sales Double — Feb 17, 2026

OTLK Analyst Consensus

2 analysts cover OTLK: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.25.

Common questions about OTLK

Who is trading OTLK stock inside the company?: Recent OTLK insider activity includes KENYON LAWRENCE A bought 5.00K, Haddadin Yezan Munther bought 1.88K, Evanson Jeff bought 62.48K, and Dagnon Terry sold 520.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OTLK?: Yes. Rallies tracks OTLK insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OTLK research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OTLK. It does not provide personalized investment advice.